@davidkzen's peptide injection basics, fact-checked

David Kasteler's TikTok covers the basics of subcutaneous injections for peptide therapy, touching on injection technique, sites, and what peptides actually do. While his information is generally accurate, the video cuts off before addressing safety considerations that matter most for anyone considering peptide treatments.

What does this video actually claim?

Kasteler explains subcutaneous injection technique using insulin needles, lists common injection sites (glutes, thighs, abdomen, hips), and defines peptides as amino acid chains that regulate metabolism, recovery, and hormone signaling. The video appears to cut off mid-sentence when he starts discussing something "very important" about peptide considerations.

He's demonstrating what looks like a standard peptide injection, likely a GLP-1 receptor agonist given the platform's categorization. The injection technique he shows matches standard protocols for medications like semaglutide or tirzepatide.

Does the science back up these injection basics?

Yes, his injection guidance is solid. Subcutaneous administration is the standard route for GLP-1 medications, with studies consistently using this method.

The STEP trials for semaglutide (Wilding et al., NEJM, 2021) used subcutaneous injections, as did the SURMOUNT trials for tirzepatide (Jastreboff et al., NEJM, 2022). Both achieved significant weight loss: 14.9% with semaglutide 2.4mg and 20.9% with tirzepatide 15mg respectively.

His injection site recommendations are standard practice. The abdomen, thigh, and upper arm are FDA-approved sites for most GLP-1 medications, with rotation between sites recommended to prevent lipodystrophy.

What's missing from this incomplete video?

The video's abrupt ending is problematic because it skips the safety discussion Kasteler was apparently about to provide. This matters more than injection technique.

Compounded GLP-1 peptides, which many social media creators promote, aren't FDA-approved and lack the safety data of brand-name versions. The FDA issued warnings in 2023 about compounded semaglutide after reports of dosing errors and contamination.

He also doesn't mention that legitimate GLP-1 medications require prescriptions and medical supervision. The STEP and SURMOUNT trials included regular medical monitoring, which isn't just regulatory box-checking but actual safety protocol.

What should you actually know about peptide injections?

Injection technique is the easy part. The hard part is getting legitimate, properly dosed medication from licensed providers.

Real semaglutide starts at 0.25mg weekly and titrates to 2.4mg over 16-20 weeks. Real tirzepatide starts at 2.5mg and goes to 15mg. These aren't arbitrary numbers but dosing schedules proven safe in clinical trials involving tens of thousands of patients.

If you're considering GLP-1 therapy, work with providers who prescribe FDA-approved versions and provide proper medical oversight. The injection technique Kasteler shows is correct, but it's meaningless if you're injecting unregulated compounds.